Denali Therapeutics Inc. (DNLI) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
37/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinDNLI / S&P 33.96% / 15.20% |
LoseDNLI / S&P DNLI unavailable / 15.00% |
LoseDNLI / S&P 1.07% / 50.40% |
| 2026-Q11/3 |
WinDNLI / S&P 16.29% / -4.33% |
LoseDNLI / S&P DNLI unavailable / 11.30% |
LoseDNLI / S&P 7.46% / 27.70% |
| 2025-Q42/3 |
WinDNLI / S&P 13.71% / 2.65% |
LoseDNLI / S&P DNLI unavailable / 9.00% |
WinDNLI / S&P 15.12% / 13.40% |
| 2025-Q30/3 |
LoseDNLI / S&P 3.79% / 8.12% |
LoseDNLI / S&P DNLI unavailable / 4.61% |
LoseDNLI / S&P 5.42% / 13.45% |
| 2025-Q20/3 |
LoseDNLI / S&P 2.91% / 10.94% |
LoseDNLI / S&P DNLI unavailable / 4.83% |
LoseDNLI / S&P -1.75% / 10.63% |
| 2025-Q11/3 |
LoseDNLI / S&P -33.29% / -4.27% |
LoseDNLI / S&P DNLI unavailable / 4.98% |
WinDNLI / S&P 176.29% / 10.57% |
| 2024-Q41/3 |
LoseDNLI / S&P -30.04% / 2.41% |
LoseDNLI / S&P -100.00% / 5.25% |
WinDNLI / S&P 136.70% / 6.15% |
| 2024-Q32/3 |
WinDNLI / S&P 25.45% / 5.89% |
LoseDNLI / S&P -100.00% / 5.89% |
WinDNLI / S&P 185.57% / 6.11% |
| 2024-Q22/3 |
WinDNLI / S&P 13.16% / 4.28% |
LoseDNLI / S&P -99.63% / 5.38% |
WinDNLI / S&P 162.39% / 5.12% |
| 2024-Q11/3 |
LoseDNLI / S&P -4.38% / 10.56% |
WinDNLI / S&P 201.22% / 5.71% |
LoseDNLI / S&P -66.20% / 5.59% |
| 2023-Q41/3 |
LoseDNLI / S&P 4.02% / 11.69% |
WinDNLI / S&P 214.60% / 6.81% |
LoseDNLI / S&P -58.08% / 7.78% |
| 2023-Q31/3 |
LoseDNLI / S&P -30.09% / -3.27% |
WinDNLI / S&P 217.55% / 7.52% |
LoseDNLI / S&P -60.73% / -5.03% |
| 2023-Q22/3 |
WinDNLI / S&P 28.08% / 8.74% |
WinDNLI / S&P 202.18% / 9.50% |
LoseDNLI / S&P -53.02% / -8.57% |
| 2023-Q12/3 |
LoseDNLI / S&P -17.15% / 7.50% |
WinDNLI / S&P 18.33% / 10.77% |
WinDNLI / S&P 22.65% / -15.69% |
| 2022-Q42/3 |
LoseDNLI / S&P -9.38% / 7.56% |
WinDNLI / S&P 115.93% / 11.88% |
WinDNLI / S&P 8.79% / -17.99% |
| 2022-Q31/3 |
WinDNLI / S&P 4.28% / -4.88% |
LoseDNLI / S&P -69.59% / 13.47% |
LoseDNLI / S&P -584.31% / -1.41% |
| 2022-Q21/3 |
WinDNLI / S&P -8.52% / -16.10% |
LoseDNLI / S&P -68.51% / 13.71% |
LoseDNLI / S&P -451.52% / 11.04% |
| 2022-Q10/3 |
LoseDNLI / S&P -27.87% / -4.60% |
LoseDNLI / S&P -75.62% / 15.97% |
LoseDNLI / S&P -490.00% / 42.23% |
| 2021-Q40/3 |
LoseDNLI / S&P -11.60% / 11.03% |
LoseDNLI / S&P -85.50% / 15.00% |
LoseDNLI / S&P -479.37% / 96.40% |
| 2021-Q31/3 |
LoseDNLI / S&P -35.68% / 0.58% |
WinDNLI / S&P 1411.32% / 10.77% |
LoseDNLI / S&P DNLI unavailable / 69.42% |
| 2021-Q22/3 |
WinDNLI / S&P 37.37% / 8.55% |
WinDNLI / S&P 1199.61% / 6.58% |
LoseDNLI / S&P DNLI unavailable / 51.81% |
| 2021-Q11/3 |
LoseDNLI / S&P -31.83% / 6.17% |
WinDNLI / S&P 1219.56% / -1.06% |
LoseDNLI / S&P DNLI unavailable / 7.39% |
| 2020-Q42/3 |
WinDNLI / S&P 133.77% / 12.15% |
WinDNLI / S&P 1174.93% / -3.72% |
LoseDNLI / S&P DNLI unavailable / -33.42% |
| 2020-Q31/3 |
WinDNLI / S&P 48.18% / 8.93% |
LoseDNLI / S&P -84.15% / -2.04% |
LoseDNLI / S&P DNLI unavailable / -27.10% |
| 2020-Q21/3 |
WinDNLI / S&P 38.09% / 20.54% |
LoseDNLI / S&P -79.65% / -0.46% |
LoseDNLI / S&P DNLI unavailable / -27.11% |
| 2020-Q11/3 |
WinDNLI / S&P 0.52% / -19.60% |
LoseDNLI / S&P -80.57% / 3.47% |
LoseDNLI / S&P DNLI unavailable / -14.75% |
| 2019-Q41/3 |
WinDNLI / S&P 13.71% / 9.07% |
LoseDNLI / S&P -79.61% / 5.36% |
LoseDNLI / S&P DNLI unavailable / 2.99% |
| 2019-Q31/3 |
LoseDNLI / S&P -26.20% / 1.70% |
WinDNLI / S&P 4128.85% / 5.02% |
LoseDNLI / S&P DNLI unavailable / 0.21% |
| 2019-Q21/3 |
LoseDNLI / S&P -10.59% / 4.30% |
WinDNLI / S&P 5798.65% / 6.64% |
LoseDNLI / S&P DNLI unavailable / 8.65% |
| 2019-Q11/3 |
LoseDNLI / S&P 12.39% / 13.65% |
WinDNLI / S&P 20581.75% / 8.12% |
LoseDNLI / S&P DNLI unavailable / 14.29% |
| 2018-Q41/3 |
WinDNLI / S&P -4.97% / -13.52% |
LoseDNLI / S&P DNLI unavailable / 9.05% |
LoseDNLI / S&P DNLI unavailable / 18.23% |
| 2018-Q31/3 |
WinDNLI / S&P 42.56% / 7.71% |
LoseDNLI / S&P DNLI unavailable / 10.21% |
LoseDNLI / S&P DNLI unavailable / 19.06% |
| 2018-Q20/3 |
LoseDNLI / S&P -22.55% / 3.43% |
LoseDNLI / S&P DNLI unavailable / 9.03% |
LoseDNLI / S&P DNLI unavailable / 14.46% |
| 2018-Q11/3 |
WinDNLI / S&P 25.90% / -0.76% |
LoseDNLI / S&P DNLI unavailable / 7.68% |
LoseDNLI / S&P DNLI unavailable / 12.46% |
| 2017-Q40/3 |
LoseDNLI / S&P DNLI unavailable / 6.64% |
LoseDNLI / S&P DNLI unavailable / 7.03% |
LoseDNLI / S&P DNLI unavailable / 13.82% |
| 2017-Q30/3 |
LoseDNLI / S&P DNLI unavailable / 4.48% |
LoseDNLI / S&P DNLI unavailable / 5.68% |
LoseDNLI / S&P DNLI unavailable / 17.57% |
| 2017-Q20/3 |
LoseDNLI / S&P DNLI unavailable / 3.09% |
LoseDNLI / S&P DNLI unavailable / 4.83% |
LoseDNLI / S&P DNLI unavailable / 17.74% |
| 2017-Q10/3 |
LoseDNLI / S&P DNLI unavailable / 6.07% |
LoseDNLI / S&P DNLI unavailable / 3.67% |
LoseDNLI / S&P DNLI unavailable / 13.32% |
| 2016-Q40/3 |
LoseDNLI / S&P DNLI unavailable / 3.82% |
LoseDNLI / S&P DNLI unavailable / 2.09% |
LoseDNLI / S&P DNLI unavailable / 7.05% |
| 2016-Q30/3 |
LoseDNLI / S&P DNLI unavailable / 3.85% |
LoseDNLI / S&P DNLI unavailable / 0.20% |
LoseDNLI / S&P DNLI unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | DNLI total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 61.56% | 20.78% |
| Annualized return | 61.56% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | DNLI total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -55.31% | 83.14% |
| Annualized return | -14.88% | 12.86% |
10Y · 2017-12-08 to 2026-08-27
| Metric | DNLI total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 15.01% | 319.30% |
| Annualized return | 1.41% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |